Leech Therapy for Knee Osteoarthritis

Moderate-strong evidence: 60–80% response rate with pain reduction lasting 2–6 months

Ensayos clínicosASH Evidence Compendium (2026)— ASH Clinical ReferenceDOI →

Por qué esto importa para la hirudoterapia

Strongest evidence for any off-label hirudotherapy indication. Pain reduction comparable to intra-articular corticosteroid injections but with longer duration (6+ months vs 6–8 weeks). GRADE assessment: MODERATE quality, conditional positive recommendation.

Evidencia clínica — No evaluada por la FDA

Uso experimental. Hirudoterapia para OA de rodilla no aprobada por FDA. Revisión educativa.

Última actualización: April 3, 2026Revisado por: ASH Medical Advisory Board

Evaluación GRADE

MODERATE

GRADE Quality

60–80%

Response rate

2–6 mo

Benefit duration

Positive

Conditional recommendation

Ensayos clínicos clave

Michalsen et al. (2003)

Annals of Internal Medicine · PMID: 14597472

Landmark RCT (n=51) comparing single leech application vs. topical diclofenac for knee OA. Pain reduction: 38.6 mm vs. 8.4 mm on VAS (p<0.001). Benefits lasted 4+ weeks with significant function improvement.

−38.6 mm

Leech group (VAS)

−8.4 mm

Diclofenac group (VAS)

p<0.001

Statistical significance

Michalsen et al. (2008)

Rheumatology · PMID: 18567915

Comparative effectiveness study showing leech therapy comparable to intra-articular corticosteroid injection for knee OA, with longer-lasting benefits (6+ months vs. 6–8 weeks for steroids).

Rossi et al. (2018) — Systematic Review

Evidence-Based Complementary and Alternative Medicine · PMID: 30210547

Systematic review of 5 RCTs (n=327 patients) concluding moderate-quality evidence for clinically meaningful pain reduction with leech therapy for osteoarthritis.

Protocolo y selección de pacientes

Treatment Protocol

Initial course: 4–6 sessions, weekly
Leeches per session: 4–8 (around knee joint)
Duration: 45–60 minutes per session
Maintenance: Every 2–3 months if symptoms recur
Combination: With physical therapy and weight management

Patient Selection

Confirmed knee OA (radiographic)
Failed conservative treatment (3+ months)
Unable to tolerate NSAIDs
Realistic expectations about outcomes

Resultados esperados

Outcome	Expected Value
Pain reduction in responders	50–80%
Function improvement	Better mobility, reduced stiffness
Duration of effect	2–6 months
Response rate	60–80%

Regulatory status

Leech therapy for osteoarthritis is not FDA-cleared. The FDA 510(k) clearance is limited to relief of venous congestion in microsurgical procedures. Use for OA is investigational/off-label in the United States.

Aviso legal — investigación y educación

La información en esta página se proporciona únicamente con fines educativos e informativos y no constituye asesoramiento médico, diagnóstico o recomendaciones de tratamiento. Los resúmenes de evidencia clínica reflejan la literatura publicada revisada por pares y no implican eficacia terapéutica fuera de los contextos autorizados por la FDA.

La autorización FDA 510(k) para sanguijuelas medicinales se limita a indicaciones específicas. Las aplicaciones en investigación y fuera de indicación se identifican como tales. Los profesionales deben consultar las directrices vigentes de la FDA, los protocolos institucionales y las normativas estatales aplicables antes del uso clínico.

ASH apoya la evaluación rigurosa basada en evidencia de todas las aplicaciones de hirudoterapia mediante ensayos clínicos controlados e investigación revisada por pares.

Referencias

[R1]
Effectiveness of Leech Therapy in Osteoarthritis of the Knee: A Randomized, Controlled Trial
Annals of Internal Medicine(2003)https://pubmed.ncbi.nlm.nih.gov/14597472/
Michalsen et al. n=51, pain reduction 38.6 mm vs 8.4 mm (p<0.001).
[R2]
Comparative Effectiveness: Leech Therapy vs Intra-Articular Steroid for Knee OA
Rheumatology(2008)https://pubmed.ncbi.nlm.nih.gov/18567915/
Michalsen et al. Comparable efficacy, longer duration than steroids.
[R3]
Systematic Review: Leech Therapy for OA (5 RCTs, n=327)
Evidence-Based Complementary and Alternative Medicine(2018)https://pubmed.ncbi.nlm.nih.gov/30210547/
Rossi et al. Moderate-quality evidence for symptom improvement.

← Todos los artículos de investigación

Añadido a la biblioteca ASH: April 3, 2026 | Última actualización del sitio: March 18, 2026